,
Shawn E Lupold, Ph.D.

Associate Professor of Urology and Oncology
Catherine Iola and J. Smith Michael Distinguished Chair in Urology
Johns Hopkins University School of Medicine

Co-Director
Sidney Kimmel Comprehensive Cancer Center Prostate Cancer Program

Secondary Appointments and Affiliations
Radiation Oncology and Molecular Radiation Sciences
Johns Hopkins Institute for NanoBioTechnology

Address:
School of Medicine 600 N Wolfe St, Park 209 Baltimore, MD 21287

Appointments: (410) 502-4822

Email: slupold1@jhmi.edu

Fax: 410-502-7711

Shawn E. Lupold, Ph.D., is Associate Professor of Urology and Oncology and the Catherine Iola and J. Smith Michael Distinguished Chair in Urology.  He serves as co-director of the Prostate Cancer Program for the Sidney Kimmel Comprehensive Cancer Center.  Dr. Lupold was trained as a Pre-IRTA fellow in the Laboratory of Human Carcinogenesis at the National Cancer Institute and received his Ph.D. in Pharmacology and Molecular Sciences from the Johns Hopkins University School of Medicine.  He further trained in prostate cancer research as a postdoctoral fellow in the Brady Urological Research Institute at Johns Hopkins.

The focus of the Lupold laboratory is noncoding RNAs and RNA-based therapeutics.  The laboratory applies cutting edge techniques to study the role of noncoding RNAs in prostate cancer biology and to develop new approaches for cancer diagnostics, prognostics, and therapy. 



Education


1988- 1992

B.S., Biology; Dept of Life Sciences,
University of Maryland, College Park, MD

1993-1995

Pre-IRTA Fellow, Laboratory of Human Carcinogenesis,
National Institutes of Health, National Cancer Institute, Bethesda, MD

1995-2001 

Ph.D., Department of Pharmacology and Molecular Sciences,        
Biochemistry, Cellular, and Molecular Biology Graduate Program
The Johns Hopkins University School of Medicine, Baltimore, MD

2001-2005

Post Doctoral Fellow, Department of Urology,
The Johns Hopkins University School of Medicine, Baltimore, MD



Publications


Free Access to abstracts at PubMed


  SELECTED PUBLICATIONS
  1. Mukherjee A, Kumar B, Hatano K, Russell LM, Trock BJ, Searson PC, Meeker AK, Pomper MG and Lupold SE. Development and application of a novel model system to study ‘active’ and ‘passive’ tumor targeting.  Mol Cancer Ther. 2016, Aug 2. [Epub ahead of print]

  2. Kumar B and Lupold SE. MicroRNA Expression and Function in Prostate Cancer: A Review of Current Knowledge and Opportunities for Discovery. Asian J Androl. Asian J Androl. 2016 Jul-Aug;18(4):559-67. PMCID: PMC4955179

  3. Castanares MA, Copeland BT, Chowdhury WH, Liu MM, Rodriguez R, Pomper MG, Lupold SE, and Foss CA.  Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.  The Prostate. 2016 Feb;76(2):215-25. PMCID: PMC4729204

  4. Ni X, Zhang Y, Zennami K, Castanares M, Mukherjee A, Raval RR, Zhou H, DeWeese TL, and Lupold SE. Systemic administration and targeted radiosensitization via chemically synthetic aptamer-siRNA chimeras in human tumor xenografts. Mol Cancer Ther. 2015 Dec;14(12):2797-804. PMCID: PMC4674319

  5. Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, Ni X, Kudrolli TA, Chowdhury WH, Rodriguez R, DeWeese TL, and Lupold SE.  A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation.  Nucleic Acids Res 2015 Apr 30;43(8):4075-86.  PMCID:  PMC4417178
  1. Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Mease RC, Ma R, Mukherjee A, Lupold SE, Pomper MG, and Rodriguez R.  Real-time, near –infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. Clin Cancer Res. 2015 Feb 15;21(4):771-80.  PMCID: PMC4334690
  2. Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli TA, Meeker AK, De Marzo AM, Platz EA, and Lupold SE.  Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.  Prostate. 2014 Dec;74(16):1655-62.  PMCID:    PMC4205269
  1. Wu P, Sokoll LJ, Kudrolli TA, Chowdhury WH, Ma R, Liu MM, Rodriguez R, Lupold SE. A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector. Prostate. 2014 Sep;74(13):1286-96. PMCID: PMC4130793

  2. Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease R, Wang Y, Rodriguez R, Lupold SE*, and Pomper MG*.  The development and evaluation of Prostate Specific Membrane Antigen as a novel imaging reporter. J Nucl. Med 2014.  May;55(5):805-11. PMCID: PMC4074907 (*equal contribution)
  1. Mukherjee A, Castanares M, Hedayati M, Wabler M, Trock B, Kulkarni P, Rodriguez R, Getzenberg RH, DeWeese TL, Ivkov R*, and Lupold SE*. Monitoring nanoparticle mediated cellular hyperthermia with a high sensitivity biosensor.  Nanomedicine (Lond). 2014.  February 18.  [Epub ahead of Print]
  2. Mukherjee A, Darlington T, Baldwin R, Holz C, Olsen S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R and Lupold SE.  Development and screening of a series of antibody-conjugated and silica coated ironoxide nanoparticles for targeting the Prostate Specific Membrane Antigen.  ChemMedChem 2014, Jul;9(7):1356-60. PMCID: PMC4082462
  1. Ribas J*, Ni X*, Castanares M, Liu M, Rodriguez R, Mendell JT, and Lupold SE. A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts.  Nucleic Acids Res. 2012 Aug 1;40(14):6821-33. PMCID: PMC3413119 (*equal contribution)

  2. Lupold SE, Johnson T, Chowdhury WH, and Rodriguez R.  A real time Metridia Luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the β-actin promoter and enhancer.  PLoS ONE 7(5): e36535, 2012
  1. Ni X, Castanares M, Mukherjee A, and Lupold SE.  Nucleic Acid Aptamer: clinical applications and promising new horizons.  Cur Med Chem. 18(27), 4206-4214, 2011

  2. Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.  Journal of Clinical Investigation.  J Clin Invest. 2011 Jun 1;121(6):2383-90.

  3. Wu P, Kudrolli TA, Chowdhury WH, Minzhi ML, Rodriguez R, and Lupold SE.  Adenovirus Targeting to Prostate-specific Membrane Antigen through Virus displayed Semi-random Peptide Library Screening.  [Priority Report] Cancer Res. 2010 Dec 1;70(23):9549-53.

  4. Ribas J and Lupold SE.  The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle; 9(5), 923-9, 2010
  1. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi1 AH, Chowdhury WE, Kudrolli TA, Yegnasubramanian A, Luo J, Rodriguez T, Mendell JT, Lupold SE.  miR-21:  An androgen receptor regulated microRNA which promotes hormone dependent and independent prostate cancer growth.  Cancer Research. [Priority Report]  69(18): 7165-9, 2009   

  2. Lupold SE., Kudrolli T., Chowdhury W., Wu P, and Rodriguez R. “A Novel Method for Generating and Screening Peptides and Libraries Displayed on Adenovirus Fiber” Nucl. Acids Res. 35(20):e138, 1-10, 2007
  1. Lupold SE, Rodriguez R.  “Adenoviral Vectors for Prostate Cancer Gene Therapy” Cancer Therapy, Vol 3, 267-284, 2005

  2. Lupold SE, Rodriguez R. “Adenoviral Gene Therapy, Radiation, and Prostate  Cancer” Reviews in Urology; Vol 7(4), 193-202. Fall 2005

  3. Lupold SE., Rodriguez R.  Disulfide-Constrained Peptides that Bind to the Extracellular Portion of the Prostate Specific Membrane Antigen.  Mol Cancer Ther. 3(5):597-603, 2004

  4. Lupold SE., Hicke B.J., Lin Y., Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research. 62(14):4029-33, 2002.


  BOOK CHAPTERS
  1. Ribas J and Lupold SE.  Role of miR-21, and androgen-regulated microRNA, in prostate cancer, In Androgen Responsive Genes in Prostate Cancer, Springer, 2012Chapter 18, in Androgen-Responsive Genes in Prostate Cancer.  Regulation, Function and Clinical Applications.  Springer, 2013

  2. Byun Y, Mease RC, Lupold SE, Pomper MG. Recent Development of Diagnostic and Therapeutic Agents Targeting Glutamate Carboxypeptidase II (GCPII), Chapter 36, In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications.  Wiley, 2009

  OTHER MEDIA
  1. Lupold SE.  Molecular Approaches to Prostate Cancer, Johns Hopkins Medicine Podcast, 2008

 



Patents


  1. Lupold SE, Lin Y, Hicke BJ, Coffey DS. “Nucleic Acid Ligands to the Prostate Specific Membrane Antigen” US 6,933,114. Awarded 08/23/05

  2. Rodriguez R., Lupold SE, and Chowdhury WH “Peptides for Targeting the Prostate Specific Membrane Antigen” US 7,749,986. Awarded 07/06/2010

  3. Rodriguez R., Lupold SE, and Chowdhury WH, Kudroli, TA  “Adenoviral fiber exchange shuttle system”. US 8,088,621. Awarded 01/03/12

  4. Lupold SE, Rodriguez R, Chowdhury WH, and Kudrolli TA.  “Compositions and methods for generating and screening adenoviral libraries”. USPA 20090074658, March 19, 2009

  5. Lupold SE, DeWeese TL, Ni X, and Zhang Y. “Radiation sensitization agents for prostate cancer”. USPA 20130123566, May 16, 2013

  6. Lupold SE, Wu P, and Rodriguez R. “Compositions and methods for retargeting virus constructs”. USPA 20130315870, November 28, 2013

  7. Lupold SE, Chowdhury WH, Wu P, and Rodriguez R. “Compositions and methods for detecting and quantifying circulating tumor cells (CTCs).  USPA 20140017668, January 16, 2014

 

 



Membership


  • 1999-Present  American Association for Cancer Research

  • 2003-Present  American Society of Gene and Cell Therapy

  • 2006-Present  Society for Basic Urologic Research



Awards & Honors


1993  Pre-doctoral Intramural Research Training Award (IRTA)
2004   Prostate Cancer Foundation Career Development Award
2005  CPDR Distinguished Lecturer
2006   Virginia and Warren Schwerin Scholar
2007 BioVision.Nxt Fellow
2008 Department of Defense PCRP New Investigator
Award
2009 Society for Basic Urologic Research Young
Investigator Award
2009 Phyllis and Brian L. Harvey Scholar